# Infliximab Accelerated Induction in Moderate to Severe Pediatric UC

> **NCT03209232** · NA · TERMINATED · sponsor: **Schneider Children's Medical Center, Israel** · enrollment: 10 (actual)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **DRUG:** Infliximab

## Key facts

- **NCT ID:** NCT03209232
- **Lead sponsor:** Schneider Children's Medical Center, Israel
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-04-16
- **Primary completion:** 2021-09-01
- **Final completion:** 2021-09-01
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Difficulty to recruit patients and as high dose infliximab for severe UC is now the rule rather than the exception
- **Last updated:** 2021-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03209232

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03209232, "Infliximab Accelerated Induction in Moderate to Severe Pediatric UC". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03209232. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*